一、审议通过《关于使用自有资金支付募投项目人员费用并以募集资金等额置换 的议案》 监事会认为：公司根据实际需要使用自有资金先行支付募投项目人员费用，后续 定期以募集资金专项账户划转等额款项至公司相关自有资金账户，能够提高资金使用 效率，不影响公司募投项目和日常经营的正常开展，不存在变相改变募集资金用途和 损害公司及股东利益的情形，符合公司发展的需要。综上，监事会同意使用自有资金 支付募投项目人员费用并以募集资金等额置换事项。 表决结果：同意票3票，反对票0票，弃权票0票。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《广州 慧智微电子股份有限公司关于使用自有资金支付募投项目人员费用并以募集资金等额 置换的公告》（公告编号：2025-027）。 二、审议通过《关于注销2021年股票期权激励计划部分股票期权的议案》 证券代码：688512 证券简称：慧智微 公告编号：2025-026 广州慧智微电子股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州慧智微电子股份有限公司（以下简 ...

Core Viewpoint - The announcement details the first vesting period of the 2024 restricted stock incentive plan for Changzhou Juhe New Materials Co., Ltd, confirming that 1.2715 million shares will vest for 142 eligible participants based on performance criteria [1][10][21] Group 1: Incentive Plan Overview - The total number of restricted shares to be granted under the incentive plan is 3.8 million, accounting for approximately 1.57% of the company's total share capital [1] - The first grant consists of 3.586 million shares, representing about 1.48% of the total share capital at the time of the announcement [1] - The vesting schedule includes three periods: 40% after 12 months, 30% after 24 months, and 30% after 36 months [1][2] Group 2: Performance Assessment Criteria - The performance assessment for the first vesting period requires a revenue growth rate of at least 20% based on 2023 figures [2][3] - The second and third vesting periods have higher targets of 44% and 72.8% revenue growth, respectively [3] - The assessment will also consider the growth rate of photovoltaic conductive silver paste shipments, with similar percentage targets [2][3] Group 3: Vesting Conditions and Procedures - The board confirmed that the first vesting period conditions have been met, allowing for the vesting of 1.2715 million shares [10][21] - The vesting is contingent upon the company not having any adverse audit opinions or regulatory issues in the past year [11][12] - The company will process the vesting and related share registration according to regulatory guidelines [20] Group 4: Stock Grant Details - The adjusted grant price for the restricted shares is set at 18.33 yuan per share, down from 18.74 yuan due to a rights issue [8][9] - A total of 142 individuals are eligible for the first vesting, with specific performance ratings determining individual share allocation [18][19] - The company has invalidated 38.05 thousand shares due to the departure of certain participants [9][15]

证券代码：688136 证券简称：科兴制药 公告编号：2025-048 科兴生物制药股份有限公司 关于 2024 年限制性股票激励计划第一个归属期归属结果 暨股份上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 本次股票上市流通总数为1,615,000股。 ? 本次股票上市流通日期为2025 年 7 月 16 日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司有关业务规则的规定，科兴生物制药股份有限公司(以下简称"公 司")于近日收到中国证券登记结算有限责任公司上海分公司出具的《证券变更登记 证明》，公司已完成 2024 年限制性股票激励计划（以下简称"本激励计划"）第一个 归属期归属（以下简称"本次归属"）的股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 于公司<2024 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2024 年限制性股票 ...

Core Viewpoint - The company has announced the achievement of vesting conditions for the third vesting period of the initial grant and the second vesting period of the reserved grant under the 2022 Restricted Stock Incentive Plan, allowing a total of 126 individuals to receive shares [1][2][21]. Summary by Sections Incentive Plan Overview - The 2022 Restricted Stock Incentive Plan was approved on July 4, 2022, with a total grant of 2.6 million shares, representing 1.41% of the company's total share capital at the time [2][3]. - The initial grant consisted of 2.25 million shares, with a grant price of 7.64 yuan per share [3][4]. Vesting Conditions and Achievements - For the initial grant's third vesting period, 82 individuals are eligible to receive 1.016668 million shares, while 47 individuals in the reserved grant's second vesting period are eligible for 219,912 shares [2][19]. - The adjusted vesting price is set at 4.28 yuan per share [1][19]. Performance Assessment - The performance assessment for the vesting conditions includes company-level and individual-level evaluations, with specific revenue and net profit growth targets set for the years 2022 to 2024 [5][6][18]. - The company achieved a net profit of approximately 162 million yuan for 2024, reflecting an 83.58% increase compared to 2021, thus meeting the performance criteria for the vesting conditions [18]. Adjustments and Cancellations - Adjustments to the grant price and number of shares have been made over time, with the initial grant price adjusted from 7.64 yuan to 4.28 yuan [15][24]. - A total of 93,140 shares were canceled due to individuals no longer qualifying as incentive recipients [15][23]. Compliance and Approval - The board and supervisory committee have confirmed that the vesting conditions have been met and that the incentive plan complies with relevant laws and regulations [21][23][25]. - The company will continue to fulfill its disclosure obligations as required by law [24][26].

Core Viewpoint - The company announced the cancellation of 194,000 stock options from the 2021 stock option incentive plan due to the departure of one incentive object and the expiration of the exercise period for another group of incentive objects [1][10]. Group 1: Stock Option Incentive Plan - The total number of stock options reserved in the 2021 stock option incentive plan is 5.5 million, with an exercise price set at 4 yuan per registered capital [1]. - The company has made adjustments to the stock option plan, including a reduction in the total number of options to no more than 22 million and a new exercise price of 1 yuan per share [3]. - The board approved the exercise of stock options for 57 incentive objects during the first exercise period, while 320,000 options were canceled due to the departure of 5 incentive objects [4][10]. Group 2: Cancellation of Stock Options - The cancellation of stock options includes 48,000 options from one departing incentive object and 146,000 options that were not exercised by another group after the expiration of their exercise period [10]. - The cancellation aligns with the regulations of the 2021 stock option incentive plan and will not materially affect the company's financial status or operational results [10][11]. - The supervisory board confirmed that the cancellation complies with the relevant provisions of the stock option incentive plan and does not harm the interests of the company or its shareholders [10].

Core Viewpoint - The company, *ST Changfang, has successfully resolved previous audit issues and removed the delisting risk warning, indicating a positive turnaround in its management and operations [1][2]. Group 1: Company Background and Issues - In 2020 and 2021, the subsidiary Kangmingsheng's original management team inflated profits and accounts receivable through undisclosed sales rebates [1]. - The company faced delisting risk warnings due to negative audit reports for the fiscal year 2021 and internal control issues [1]. - In August 2022, the company took over Kangmingsheng and initiated improvements in internal controls, removing the original management team to ensure compliance and stability [1]. Group 2: Remediation and Current Status - By April 2023, the audit firm Zhongxing Caiguanghua confirmed that the issues from the 2021 audit report had been resolved, leading to the application for the removal of the delisting risk warning [2]. - In April 2024, the company received a clean internal control audit report for 2023, further solidifying its compliance status [2]. - The original management team responsible for the issues has been dismissed, and the company has received a formal conclusion on its information disclosure violations [2]. Group 3: Future Outlook - The company plans to implement equity incentives for core personnel by the end of 2024 to enhance management and performance [3]. - It aims to explore various merger and acquisition opportunities while improving operational standards and performance [3]. - The company anticipates leveraging its newly regained status to advance its development and provide returns to investors and society [3].

法律意 中国 深圳 福田区 益田路6001号太平金融大厦11、12楼 邮政 编码：518038 电话（Tel.）：（0755）8826 5288 传真（Fax.）：（0755）8826 5537 网址（Website）：https://www.sundiallawfirm.com 法律意见书 见书 关于深圳市德明利技术股份有限公司 调整预留授予价格及授予数量的 法 律 意 见 书 广东信达律师事务所 关于深圳市德明利技术股份有限公司 调整预留授予价格及授予数量的 法律意见书 信达励字（2025）第 091 号 致：深圳市德明利技术股份有限公司 广东信达律师事务所（以下简称"信达"）根据深圳市德明利技术股份有限公 司（以下简称"公司"）与签订的《专项法律顾问聘请协议》，接受公司委托，担 任公司 2024 年限制性股票激励计划（以下简称"本次激励计划"）的专项法律顾问。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股权激 励管理办法》（以下简称《管理办法》）、《深圳证券交易所上市公司自律监管指 南第 1 号——业务办理》（以下简称《自律监管指南》）等有关法律、法规和规范 性文件以及《深圳市德明利 ...

《和元生物技术（上海）股份 证券代码：688238 证券简称：和元生物 公告编号：2025-052 和元生物技术（上海）股份有限公司 董事会薪酬与考核委员会关于公司 2025 年限制性股票激励 计划首次授予激励对象名单的审核意见及公示情况说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 和元生物技术（上海）股份有限公司（以下简称"公司"）于2025年6月27 日召开了第四届董事会第一次会议，审议通过了《关于公司<2025年限制性股票 激励计划（草案）>及其摘要的议案》等相关议案。根据《上市公司股权激励管 理办法》（以下简称"《管理办法》"）等相关规定，公司对2025年限制性股票 激励计划（以下简称"本次激励计划"）首次授予激励对象名单在公司内部进行 了公示。公司董事会薪酬与考核委员会结合公示情况对拟激励对象进行了核查， 相关公示情况及核查意见如下： 一、公示及核查情况 了《和元生物技术（上海）股份有限公司2025年限制性股票激励计划（草案）》 （以下简称"《激励计划（草案）》"）及其摘要、 有限公司2025年限制性股票 ...

证券代码：688500 证券简称：慧辰股份 公告编号：2025-045 北京慧辰资道资讯股份有限公司 关于 2025 年限制性股票激励计划第一类限制性股票 授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 第一类限制性股票登记日：2025 年 7 月 9 日 一、第一类限制性股票授予情况 （一）第一类限制性股票授予情况 公司根据 2024 年年度股东大会授权，于 2025 年 5 月 16 日召开的第四届董 事会第二十一次会议、第四届监事会第十五次会议，审议通过了《关于向 2025 年限制性股票激励计划激励对象授予限制性股票的议案》，本次激励计划第一类 限制性股票实际授予情况如下： 股普通股为 95.86 万股，来源于公司向激励对象定向发行的公司 A 股普通股 92.22 万股； 鉴于公司董事、高级管理人员何伟先生通过员工持股平台文昌琢朴企业管理 事务所（有限合伙）（以下简称"琢朴管理"）间接持有公司股份，琢朴管理于 持公司股票 1,416,500 股。出于审慎性考虑，为避免可能触及的短线交 ...

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 深圳市德明利技术股份有限公司（以下简称"公司"或"德明利"）于 2025 年 7 月 10 日召开第二届董事会第三十次会议、第二届监事会第二十八次会议， 审议通过了《关于调整 2024 年限制性股票激励计划预留部分已获授但尚未登记 的限制性股票授予数量及授予价格的议案》。由于公司实施了 2024 年度权益分 派，公司董事会根据公司《2024 年限制性股票激励计划（草案）》的相关规定及 公司 2024 年第二次临时股东大会授权等，对 2024 年限制性股票激励计划预留部 分已授予但尚未登记的限制性股票的授予数量、授予价格进行相应调整。现将有 关情况公告如下： 一、2024 年限制性股票激励计划已履行的决策程序和信息披露情况 议，审议通过了《关于公司〈2024 年限制性股票激励计划（草案）〉及其摘要的 议案》《关于公司<2024 年限制性股票激励计划实施考核管理办法>的议案》。 于公司〈2024 年限制性股票激励计划（草案）〉及其摘要的议案》《关于公司 <2024 年限制性股票激励计划实施考核管理办法>的议案》《关 ...